EBS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.09
Percentage change -1.22	%

Peers: MRNA SNY NVAX DVAX INBX OCGN VXRT ADMA XERS HEPA

| Held by: AVUV VTI IWM XBI VXF PRFZ CALF FNDA IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.71	Insider Own	4.35%	Shs Outstand	54.50M	Perf Week	9.82%
Market Cap	394.60M	Forward P/E	5.82	EPS next Y	1.25	Insider Trans	0.30%	Shs Float	51.92M	Perf Month	9.00%
Enterprise Value	914.50M	PEG	-	EPS next Q	-0.10	Inst Own	66.19%	Short Float	19.28%	Perf Quarter	70.66%
Income	-131.60M	P/S	0.41	EPS this Y	469.57%	Inst Trans	4.71%	Short Ratio	7.89	Perf Half Y	-27.95%
Sales	965.40M	P/B	0.72	EPS next Y	47.06%	ROA	-8.15%	Short Interest	10.01M	Perf YTD	-23.95%
Book/sh	10.14	P/C	2.58	EPS next 5Y	-	ROE	-21.63%	52W High	15.10 -51.85%	Perf Year	-21.83%
Cash/sh	2.82	P/FCF	4.18	EPS past 3/5Y	- -	ROIC	-10.76%	52W Low	4.02 80.85%	Perf 3Y	-78.27%
Dividend Est.	-	EV/EBITDA	15.53	Sales past 3/5Y	-16.20% -1.15%	Gross Margin	29.20%	Volatility	4.40% 5.57%	Perf 5Y	-91.87%
Dividend TTM	-	EV/Sales	0.95	EPS Y/Y TTM	76.88%	Oper. Margin	-5.14%	ATR (14)	0.39	Perf 10Y	-76.57%
Dividend Ex-Date	-	Quick Ratio	3.51	Sales Y/Y TTM	-18.56%	Profit Margin	-13.63%	RSI (14)	60.79	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	6.32	EPS Q/Q	588.34%	SMA20	8.27%	Beta	1.98	Target Price	13.50
Payout	-	Debt/Eq	1.22	Sales Q/Q	-26.03%	SMA50	14.61%	Rel Volume	0.86	Prev Close	7.36
Employees	900	LT Debt/Eq	1.21	Earnings	May 07 AMC	SMA200	-5.42%	Avg Volume	1.27M	Price	7.27
IPO	Nov 15, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	61.36% 1.46%	Trades		Volume	836,660	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$15
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$16
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy	$5
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy	$22
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$23 → $9
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy	$77
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy	$150
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$112
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$112
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$110
Sep-14-20	Resumed	JP Morgan	Neutral	$103
Jul-31-20	Reiterated	Chardan Capital Markets	Buy	$86 → $112
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform

Show Previous Ratings

Jul-08-25 04:45PM	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts (GlobeNewswire) +6.70%
Jul-02-25 04:05PM	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate (GlobeNewswire) +7.73%
Jun-23-25 08:05AM	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply (GlobeNewswire)
Jun-20-25 08:13AM	Emergent BioSolutions Announces Addition to Russell 3000 Index (GlobeNewswire)
Jun-05-25 07:00AM	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies (GlobeNewswire)
09:55AM	Loading…
May-29-25 09:55AM	5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost (Zacks)
May-19-25 09:43AM	Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions (Zacks)
May-16-25 10:52AM	5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes (Zacks) +20.95%
May-14-25 07:32AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 09:53AM	Q1 2025 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) +34.18%
03:33AM	Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... (GuruFocus.com)
May-07-25 10:03PM	Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress (Seeking Alpha)
10:01PM	Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
04:32PM	Emergent Biosolutions: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Emergent BioSolutions Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 05:07PM	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health (GlobeNewswire) -7.87%
Apr-22-25 08:00AM	Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -9.17%
Apr-09-25 08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks) +9.58%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-31-25 08:00AM	Emergent BioSolutions Announces Stock Repurchase Program (GlobeNewswire)
Mar-26-25 10:32AM	Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (SeekingAlpha) -6.00%
Mar-20-25 04:30PM	Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 (GlobeNewswire)
08:30AM	Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues (SeekingAlpha)
08:06AM	Hikma announces Health Canada approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg (GlobeNewswire)
Mar-19-25 05:01PM	Emergent BioSolutions closes sale of Bayview facility to Syngene (SeekingAlpha)
04:30PM	Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-18-25 08:00AM	Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products (GlobeNewswire)
Mar-13-25 11:00AM	Emergent signs financial investment agreement with Swiss Rockets (Pharmaceutical Technology) -10.41%
08:29AM	Loading…
08:29AM	Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs (GlobeNewswire)
Mar-12-25 08:00AM	Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates (GlobeNewswire) +11.21%
Mar-10-25 09:14AM	Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-04-25 06:59AM	Q4 2024 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) -6.44%
02:45AM	Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript (Motley Fool)
02:05AM	Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Mar-03-25 05:40PM	Emergent Biosolutions (EBS) Q4 Earnings Top Estimates (Zacks) -8.69%
04:45PM	Emergent Biosolutions: Q4 Earnings Snapshot (Associated Press Finance)
04:23PM	Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 08:55AM	Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (GlobeNewswire) -14.20%
Feb-07-25 08:06AM	Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans (GlobeNewswire)
Jan-23-25 09:01AM	Emergent seeking to reverse fortunes and become a major overdose treatment player (Pharmaceutical Technology) +5.61%
Jan-16-25 08:00AM	Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) (GlobeNewswire)
Jan-14-25 07:30AM	Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals (GlobeNewswire)
Jan-13-25 09:27AM	Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga (ansuvimab-zykl) Treatment for Ebola (GlobeNewswire)
Jan-08-25 07:45AM	Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
07:30AM	Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax (Anthrax Vaccine Adsorbed) (GlobeNewswire)
Dec-30-24 05:26PM	Why Emergent BioSolutions Stock Blasted Higher Today (Motley Fool) +11.85%
Dec-16-24 08:00AM	Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (GlobeNewswire)
Dec-03-24 06:47PM	Why Emergent BioSciences Stock Plummeted Today (Motley Fool) -5.59%
Nov-08-24 10:04AM	Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +7.00%
Nov-07-24 02:06PM	Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 (Benzinga) +19.57%
01:15AM	Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript (Motley Fool)
Nov-06-24 06:20PM	Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates (Zacks)
05:17PM	Emergent Biosolutions: Q3 Earnings Snapshot (Associated Press Finance)
04:49PM	Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa (GlobeNewswire)
04:05PM	Emergent BioSolutions Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:30AM	Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Oct-23-24 07:30AM	Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 (GlobeNewswire) -5.20%
Oct-11-24 12:33PM	Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024 (Insider Monkey)
Oct-09-24 05:09PM	Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.38%
11:09AM	Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says (Pharmaceutical Technology)
Oct-08-24 05:32PM	Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN Nasal Spray to Help Combat the Opioid Epidemic (GlobeNewswire)
Oct-02-24 07:30AM	Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility (GlobeNewswire) +8.50%
Sep-26-24 08:05AM	Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA (brincidofovir) to Support National Preparedness Efforts (GlobeNewswire) +22.56%
Sep-25-24 07:07AM	Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts (GlobeNewswire)
Sep-13-24 06:45AM	Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation (GlobeNewswire)
Sep-12-24 08:30AM	Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola (GlobeNewswire)
01:27AM	BlackRock Inc. Reduces Stake in Emergent BioSolutions Inc. (GuruFocus.com)
Sep-04-24 05:51PM	OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing (GlobeNewswire)
08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
Sep-03-24 07:08AM	Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile (GlobeNewswire) -11.07%
Aug-30-24 09:55AM	Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine (Barrons.com) -6.73%
08:33AM	This Biotech Stock Surges As WHO Health Emergency Stirs FDA Approval (Investor's Business Daily)
08:33AM	Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine (Investor's Business Daily)
08:16AM	Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness (GlobeNewswire)
04:32AM	Emergent gains FDA approval for ACAM2000 vaccine for Mpox (Pharmaceutical Technology)
Aug-29-24 06:53PM	Emergent BioSolutions' ACAM2000 , (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions (GlobeNewswire)
Aug-21-24 11:14AM	Emergent BioSolutions finalises manufacturing site sale to Bora Pharmaceuticals (Pharmaceutical Technology) +8.82%
Aug-20-24 12:03PM	Emergent joins mpox fight with 50,000 vaccine dose donation to Africa (Pharmaceutical Technology) -20.33%
11:30AM	Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals (GlobeNewswire)
Aug-19-24 05:16PM	WHO declares mpox a public health emergency as variant emerges (Yahoo Finance Video) +12.66%
05:10PM	Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa (GlobeNewswire)
Aug-16-24 04:14PM	Emergent Leads Mpox-Tied Stock Gains as Investors Await Approval (Bloomberg) +24.02%
12:51PM	Why Emergent BioSolutions Stock Is Skyrocketing Today (Motley Fool)
09:52AM	Mpox Vaccine Makers Stock Soars After Fresh WHO Warning (Barrons.com)
Aug-07-24 02:45AM	Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript (Motley Fool) -41.99%
Aug-06-24 05:14PM	Emergent Biosolutions: Q2 Earnings Snapshot (Associated Press Finance)
05:01PM	Emergent BioSolutions Reports Second Quarter 2024 Financial Results (GlobeNewswire)
08:00AM	Emergent BioSolutions Expands NARCAN Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country (GlobeNewswire)
Jul-31-24 09:06AM	SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL (Reactive Skin Decontamination Lotion) kit for $75 million (GlobeNewswire) +7.08%
08:53AM	Emergent BioSolutions Completes Sale of RSDL (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million (GlobeNewswire)
Jul-25-24 01:20PM	The stock markets cruel summer is about to get much worse (MarketWatch)
Jul-24-24 07:30AM	Emergent BioSolutions Launches Opioid Emergency Preparedness 'Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith (GlobeNewswire) +10.57%
Jul-23-24 08:27AM	Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024 (GlobeNewswire) +8.99%
Jul-22-24 08:00AM	Emergent BioSolutions Announces Shelf-Life Extension for NARCAN Nasal Spray in Canada (GlobeNewswire)
Jul-09-24 07:30AM	Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan (GlobeNewswire) +7.26%
Jul-03-24 10:13AM	Emergent scores US medical countermeasure contracts worth over $250m (Pharmaceutical Technology)
Jul-02-24 09:43AM	Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products (GlobeNewswire) +6.09%
08:13AM	Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products (GlobeNewswire)

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Katkin Keith	Director	May 23 '25	Sale	6.30	7,844	49,417	86,431	May 28 04:08 PM
KEITH KATKIN	Director	May 23 '25	Proposed Sale	6.30	7,844	49,409		May 23 04:04 PM
PAPA JOSEPH C	President and CEO	May 13 '25	Buy	5.83	60,000	349,800	342,500	May 15 04:02 PM
Fowler Neal Franklin	Director	Mar 12 '25	Sale	5.83	35,000	204,050	101,100	Mar 12 06:13 PM
Zoon Kathryn C	Director	Mar 12 '25	Sale	5.73	10,000	57,300	44,482	Mar 12 06:13 PM
Fowler Neal Franklin	Director	Mar 12 '25	Proposed Sale	5.83	35,000	204,005		Mar 12 05:34 PM
Zoon Kathryn C	Director	Mar 12 '25	Proposed Sale	5.73	10,000	57,300		Mar 12 05:23 PM
DeGolyer Donald W	Director	Nov 12 '24	Sale	10.91	25,000	272,750	111,100	Nov 14 04:18 PM
White Marvin L	Director	Nov 11 '24	Sale	11.97	14,287	171,015	54,092	Nov 13 04:04 PM
DeGolyer Donald W	Director	Nov 12 '24	Proposed Sale	11.77	25,000	294,250		Nov 12 05:16 PM
White Marvin L	Director	Nov 11 '24	Proposed Sale	11.77	14,287	168,158		Nov 12 10:34 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Emergent Biosolutions Inc

Upgrade your FINVIZ experience